Acute Spinal Cord Compression
NEJM 376:1358-1369, Ropper, A.E. & Ropper, A.H., 2017
Two-Year Outcome after Endovascular Treatment for Acute Ischemic Stroke
NEJM 376:1341-1349, Van Den Berg, L.A.,et al, 2017
Reversible Gait Ataxia
Neurol 88:e145-e149, Abkur, T.M. & Bede, P., 2017
Reduction in Time to Treatment in Prehospital Telemedicine Evaluation and Thrombolysis
Neurol 88:1305-1312, Taqui, A.,et al, 2017
Intracranial Dural Arteriovenous Fistulae
Stroke 48:1424-1431, Reynolds, M.R.,et al, 2017
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017
Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy
Stroke 48:1416-1419, Labovitz, D.L.,et al, 2017
Patient with Severe Moyamoya Disease Who Presents with Acute Cortical Blindness
Stroke 48:e126-e129, Sajja, A.,et al, 2017
Benefits of Emergency Departments Contribution to Stroke Prophylaxis in Atrial Fibrillation
Stroke 48:1344-1352, Coll-Vinent, B.,et al, 2017
A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
NEJM 376:1627-1636, Calkins, H.,et al, 2017
Intravenous Immune Globulin: Adverse Effects
UptoDate June, Perez, E.E. & Silvergleid, A.J., 2017
Lumbar Puncture Test in Normal Pressure Hydrocephalus: Does the Volume of CSF Removed Affect the Response to Tap?
AJNR 38:1456-1460, Thakur, S.K., et al, 2017
TIPIC Syndrome: Beyond the Myth of Carotidynia, a New Distinct Unclassified Entity
AJNR 38:1391-1398, Lecler, A.,et al, 2017
Amyotrophic Lateral Sclerosis
NEJM 377:162-172, Brown, R.H.,et al, 2017
Trial of Tocilizumab in Giant-Cell Arteritis
NEJM 377:317-328,385, Stone, J.H.,et al, 2017
A Demure Teenager and Her Dystonic Foot
Neurol 89:e71-e75, Cullinane, P.W.,et al, 2017
Quality Improvement in Neurology: Inpatient and Emergency Care Quality Measure Set
Neurol 89:730-735, Josephson, S.An.,et al, 2017
Long-Term Antithrombotic Treatment in Intracranial Hemorrhage Survivors with Atrial Fibrillation
Neurol 89:687-696, Korompoki, E.,et al, 2017
Effect of Gluten-Free Diet on Cerebellar MR Spectroscopy in Gluten Ataxia
Neurol 89:705-709, Hadjivassiliou, M.,et al, 2017
Migraine
NEJM 377:553-561, Charles, A., 2017
Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?
NEJM 377:411-414, Goodman, C.W. & Brett, A.S., 2017
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
NEJM 377:431-441, Pollack, C.V.,et al, 2017
CT Angiography ASPECTS Predicts Outcome Much Better Than Noncontrast CT in Patients with Stroke Treated Endovascularly
AJNR 38:1569-1573, Sallustio, F.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
Overview of IgG4-related Disease
UptoDate, July, Moutsopoulos,H.,et al, 2017
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
A Case of Altered Mental Status, Not Otherwise Specified
Neurol 89:e154-e158, Swor, D.E.,et al, 2017
Thalamic Deep Brain Stimulation for Tremor in Parkinson Disease, Essential Tremor, and Dystonia
Neurol 89:1416-1423, Cury, R.G.,et al, 2017
Diagnostic Challenges in a Young Patient with Hypereosinophilia
Neurol 89:e159-e165, Ortiz, J.G.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
National Randomized Controlled Trial of Virtual House Calls for Parkinson Disease
Neurol 89:1152-1161,1103, Beck, C.A.,et al, 2017
Zolpidem for the Treatment of Neurologic Disorders
JAMA Neurol 74:1130-1139, Bomalaski, M.N.,et al, 2017
Management of Parkinson Disease in 2017
JAMA 318:791-792, Okun, M.S.,et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
Chess Study Revives Debate Over Cognition-Enhancing Drugs
JAMA doi:10.1001/JAMA:2017.8114, Lyon, J., 2017
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke
Ann Neurol 81:849-856, Lansberg, M.G.,et al, 2017
Atrioesophageal Fistula -Clinical Presentation, Procedural Characteristics, Diagnostic Investigations, and Treatment Outcomes
Circ Arrhythrm Electrophysiol doi:10.1161/CIRCEP.117.005579, Han,H-C.,et al, 2017
Atrio-Esophageal Fistula:A Case Series and Literature Review
Am J Case Rep 18:847-854, Schuring,C.A.,et al, 2017
Central Nervous System Brucellosis Granuloma and White Matter Disease in Immunocompromised Patient
Emerg Infect Dis 23:978-981, Alqwaifly,M.,et al, 2017
Adult-Onset Niemann-Pick Disease Type C: Rapid Treatment Initiation Advised but Early Diagnosis Remains Difficult
Front Neurol doi.10.3398/jneur.2017.00108, Piroth,T.,et al, 2017
Transgender Venous Thrombosis
Neurol Clin Pract 7:531-533, Opaskar,A.,et al, 2017
Severe Acute Hyponatremia as an Initial Presentation of Acute Intermittent Porphyria Triggered by a Subdermal Etonogestrel Implant
J Nephrol Renal Ther 2:1-4, Valente, J.R.,et al, 2016
Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016
Anti-LGI1 Encephalitis
Neurol 87:1449-1456,1428, Van Sonderen, A.,et al, 2016